A Health Intersection of Toxicology and Clinical Medicine

1. Laterza, OF, Zhao, X. Biomarker discovery, translating molecular biomarkers into clinical assays. In: Weiner, R, Kelley, M, eds. American Association of Pharmaceutical Scientists Advances in the Pharmaceutical Sciences Book Series (AAPS). Switzerland: Springer International Publishing AG; 2016:27-35. doi:10.1007/978-3-319-40793-7_3.
Google Scholar | Crossref2. Biomarkers Definitions Working Group . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
Google Scholar | Crossref | Medline | ISI3. Cohen, AF, Burggraaf, J, van Gerven, JMA, Moerland, M, Groeneveld, GJ. The use of biomarkers in Human Pharmacology (phase I) studies. Annu Rev Pharmacol Toxicol. 2015;55:55-74.
Google Scholar | Crossref | Medline4. Anonymous . The sequence explosion. Nature. 2010;464:670-671.
Google Scholar | Crossref | Medline5. Weissenbach, J . The rise of genomics. C R Biol. 2016;339:231-239.
Google Scholar | Crossref | Medline6. Collins, FS, Varmus, H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
Google Scholar | Crossref | Medline | ISI7. National Research Council . Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: The National Academies Press; 2011. doi:10.17226/13284.
Google Scholar | Crossref8. Reitz, C, Mayeux, R. Alzheimer’s disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88:640-651. doi:10.1016/j.bcp.2013.12.024.
Google Scholar | Crossref | Medline | ISI9. Femminella, G, Thayanandan, T, Calsolaro, V, et al. Imaging and molecular mechanisms of Alzheimer’s disease: a review. Int J Mol Sci. 2018;19(12):3702. doi:10.3390/ijms19123702.
Google Scholar | Crossref10. Chandra, A, Dervenoulas, G, Dervenoulas, G, Politis, M. Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment. J Neurol. 2019;266:1293-1302.
Google Scholar | Crossref | Medline11. Olsson, B, Lautner, R, Andreasson, U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. The Lancet (Neurology). 2016;15:673-684.
Google Scholar | Crossref | Medline | ISI12. Blennow, K, Zetterberg, H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284:643-663.
Google Scholar | Crossref | Medline13. Hur, J-Y, Frost, GR, Wu, X, et al. The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer’s disease. Nature. 2020;586:735-740. doi:10.1038/s41586-020-2681-2.
Google Scholar | Crossref | Medline14. Budny, JA . Book review: genomic biomarkers for pharmaceutical development – advancing personalized health care. In: Yoa, Y, Jallal, B, Ranade, K, eds. Int J Tox4. San Diego, CA: Academic Press; 2014:342-343.
Google Scholar | SAGE Journals15. Budny, JA . Book review: biomarkers in toxicology. In: Gupta, RC , ed. Int J Tox. San Diego, CA: Academic Press/Elsevier; 2014:213.
Google Scholar16. Budny, JA . Commentary: the French revolution, toxicity biomarkers, and digging holes. Int J Tox. 2014;33(4):268-270.
Google Scholar | SAGE Journals | ISI

留言 (0)

沒有登入
gif